Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report)'s stock price reached a new 52-week low during trading on Tuesday . The company traded as low as $640.28 and last traded at $638.59, with a volume of 349031 shares traded. The stock had previously closed at $661.00.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on REGN. Bernstein Bank cut their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a report on Tuesday, February 4th. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research report on Monday. UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, Robert W. Baird reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $966.88.
View Our Latest Stock Analysis on REGN
Regeneron Pharmaceuticals Price Performance
The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm's 50-day moving average price is $682.93 and its two-hundred day moving average price is $791.84. The stock has a market cap of $69.34 billion, a PE ratio of 16.57, a PEG ratio of 2.34 and a beta of 0.27.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $11.86 earnings per share. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is currently 2.30%.
Hedge Funds Weigh In On Regeneron Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in REGN. D.A. Davidson & CO. raised its stake in shares of Regeneron Pharmaceuticals by 5.1% during the 3rd quarter. D.A. Davidson & CO. now owns 821 shares of the biopharmaceutical company's stock worth $863,000 after acquiring an additional 40 shares in the last quarter. Quantbot Technologies LP purchased a new position in Regeneron Pharmaceuticals in the third quarter worth $151,000. Public Sector Pension Investment Board increased its position in shares of Regeneron Pharmaceuticals by 13.0% during the third quarter. Public Sector Pension Investment Board now owns 4,341 shares of the biopharmaceutical company's stock worth $4,563,000 after purchasing an additional 500 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 87.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 73 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 34 shares during the last quarter. Finally, Captrust Financial Advisors boosted its position in shares of Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. Captrust Financial Advisors now owns 9,130 shares of the biopharmaceutical company's stock worth $9,597,000 after purchasing an additional 296 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
